RayzeBio, Inc. Common Stock
RYZB
RYZB was delisted on the 23rd of February, 2024.
107 hedge funds and large institutions have $3.41B invested in RayzeBio, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 19 increasing their positions, 18 reducing their positions, and 20 closing their positions.
195% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 20
184% more capital invested
Capital invested by funds: $1.2B → $3.41B (+$2.21B)
125% more funds holding in top 10
Funds holding in top 10: 8 → 18 (+10)
57% more funds holding
Funds holding: 68 → 107 (+39)
6% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 18
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$33.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.8M |
| 3 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$19M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$14.1M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$13.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$26.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$25.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$22.2M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$13M |
| 5 |
AG
Artal Group
Luxembourg
|
-$12.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Walleye Capital
New York
| – | -$330K | -14,847 | Closed |
|
127
Norges Bank
Oslo,
Norway
| – | -$222K | -10,000 | Closed |
|
RYZB Hedge Fund Activity: Q4 2023 in Review
107 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in RayzeBio, Inc. Common Stock (RYZB) for Q4 2023, worth a combined $3.41B — up 184% from $1.2B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new RYZB positions and 20 closed out — a net gain of 39 holders — while 19 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $33.8M. The largest seller was Capital Research Global Investors, cutting an estimated $26.8M.
- 107 institutional investors held RayzeBio, Inc. Common Stock (RYZB) as of Q4 2023, up from 68 in Q3 2023.
- Funds reported $3.41B of RayzeBio, Inc. Common Stock stock for Q4 2023, up 184% quarter-over-quarter.
- 59 funds opened new RayzeBio, Inc. Common Stock positions in Q4 2023 and 20 closed out, a net change of +39 holders.
- The largest RayzeBio, Inc. Common Stock buyer in Q4 2023 was BlackRock, an estimated $33.8M added.
- The largest RayzeBio, Inc. Common Stock seller in Q4 2023 was Capital Research Global Investors, an estimated $26.8M sold.
Based on aggregated 13F filings for Q4 2023.